179 related articles for article (PubMed ID: 28983607)
1. Iguratimod prevents ovariectomy‑induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator‑activated receptor‑γ.
Wu YX; Sun Y; Ye YP; Zhang P; Guo JC; Huang JM; Jing XZ; Xiang W; Yu SY; Guo FJ
Mol Med Rep; 2017 Dec; 16(6):8200-8208. PubMed ID: 28983607
[TBL] [Abstract][Full Text] [Related]
2. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
3. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
4. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
[TBL] [Abstract][Full Text] [Related]
5. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
6. (-)-Epicatechin 3-O-β-D-allopyranoside prevent ovariectomy-induced bone loss in mice by suppressing RANKL-induced NF-κB and NFATc-1 signaling pathways.
Hsiao HB; Wu JB; Lin WC
BMC Complement Altern Med; 2017 May; 17(1):245. PubMed ID: 28468652
[TBL] [Abstract][Full Text] [Related]
7.
Kim JH; Shin H; Kim M; Kim S; Song K; Jung HS; Sohn Y
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184079
[TBL] [Abstract][Full Text] [Related]
8. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
9. Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways.
Yang F; Su Y; Liang J; Wang K; Lian H; Chen J; Xu J; Zhao J; Liu Q
Int J Mol Med; 2023 May; 51(5):. PubMed ID: 37052260
[TBL] [Abstract][Full Text] [Related]
10. Andrographolide Inhibits Ovariectomy-Induced Bone Loss via the Suppression of RANKL Signaling Pathways.
Wang T; Liu Q; Zhou L; Yuan JB; Lin X; Zeng R; Liang X; Zhao J; Xu J
Int J Mol Sci; 2015 Nov; 16(11):27470-81. PubMed ID: 26593901
[TBL] [Abstract][Full Text] [Related]
11. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
12. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
13. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
[TBL] [Abstract][Full Text] [Related]
14. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
15. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
16. Protective Effect of Ciclopirox against Ovariectomy-Induced Bone Loss in Mice by Suppressing Osteoclast Formation and Function.
Ihn HJ; Lim J; Kim K; Nam SH; Lim S; Lee SJ; Bae JS; Kim TH; Kim JE; Baek MC; Bae YC; Park EK
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361069
[TBL] [Abstract][Full Text] [Related]
17. Cyperus Rotundus L. extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat.
Kum CJ; Kim EY; Kim JH; Lee B; Min JH; Heo J; Kim JH; Yeom M; Sohn Y; Jung HS
J Ethnopharmacol; 2017 Jun; 205():186-194. PubMed ID: 28315458
[TBL] [Abstract][Full Text] [Related]
18. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss.
Guan H; Zhao L; Cao H; Chen A; Xiao J
FASEB J; 2015 Mar; 29(3):1092-101. PubMed ID: 25466887
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of the inhibitory effects of jiangu granule‑containing serum on RANKL‑induced osteoclastogenesis.
Huang Y; Lin Y; Wu Y; Zeng J; Huang M; Guo S; Luo W; Lin H; Lin Y
Mol Med Rep; 2017 Dec; 16(6):8420-8426. PubMed ID: 28983609
[TBL] [Abstract][Full Text] [Related]
20. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
